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Abstract:
Wilhelm, Christina Marie. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2006.
Oral LD50 of Botulinum Toxin Serotype A in Guinea Pigs.
As a disease, botulism is a neuroparalytic illness resulting from the action of a potent
neurotoxin produced by (. Botulinum. Of the seven distinct C. Botulinum neurotoxin serotypes:
A. B, C, D, F, F, and G, only serotypes A, B, E and F cause human disease. The duration of
action of the seven toxin serotypes varies with serotype A having the most sustained action (i.e.
months vs. days in serotype E). This study was performed due to recently identified critical gaps
in our food safety procedures.

The goal of this study was to assess whether fresh 2% milk

provided protective qualities to Botulinum toxin serotype A (B0NT/A) against degradation in the
gastrointestinal tract. If protected this would lead to half the members of the tested population
being killed with lower doses compared to toxin delivered in a conventional delivery vehicle (i.e.
gel phosphate buffer). The model used for this study was adult male and female specific
pathogen free Hartley guinea pigs. The pathophysiologic effects on guinea pigs following oral
administration of BoNT/A was determined through daily clinical observations and utilization of
telemetry implants allowing examination of changes in the mean, systolic, diastolic and pulse
pressures, electrocardiogram (ECG), temperature, activity, respiratory rate, and heart rate. No
difference was shown between the two treatment groups of 2% milk and gel phosphate buffer
with respect to the time to first clinical sign or time to death. The LD50 of BoNT/A in 2% milk
was not significantly different from BoNT/A in gel phosphate buffer indicating that the milk did
not provide protective qualities in combination with the toxin.
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INTRODUCTION
(]lostridium botulinurn (first termed botulus', from the Latin word for sausage) is a spore
forming gram positive, rod-shaped bacterium approximately 0.5-2.0im in width and I .6-22.Oiim
in length normally found in soil, water, and the intestinal tracts of humans and other animals. It
was studied in the 1 800s by Justinus Kerner, who noted several important observations about the
bacteria and its toxins in his studies, including survival under anaerobic conditions, interruption
of motor signal transmission, and lethality in small doses (Ting and Freiman, 2004).
As a disease, botulism is a neuroparalytic illness resulting from the action of a potent
neurotoxin produced by C. botulinum. Common symptoms in humans include ptosis, dry mouth,
fatigue, muscle weakness, constipation, ataxia, diarrhea, paresthesia, vomiting, reduced or failed
reflexes, double/blurred vision, dysarthria and dysphagia. Paralysis from the disease presents as
an acute, symmetrical descending paralysis accompanied by multiple cranial nerve palsies
[(Shapiro et a!., 1998) and (Amon et al., 2001)]. Deaths most commonly occur from respiratory
failure.
Of the seven distinct C. botulinum neurotoxin serotypes: A, B, C, D, B, F, and G, only
serotypes A, B, E and F cause disease in humans. Each distinct serotype is produced by a
distinct strain of C. botulinum (Paiva et al., 1993). These neurotoxins are antigenically distinct
but comparable in basic structure. Each toxigenic Clostridia produces a relatively inactive
polypeptide of 150 kDa activated by proteases activated by the organism itself or gastrointestinal
enzymes of the affected animal (US Department of Health and Human Services, 1998). The
duration of action of the seven toxin sérotypes varies, although serotype A is known to have the
most sustained action (Foran et a!., 2003; Keller and Neale, 2001; Raciborska and Charlton,
1999). In comparison, Serotype A can cause paralysis for many months whereas Sertotype E
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(both acting on SNAP-25) blockade lasts for brief periods. As described in a recent article on an
outbreak of botulism in Italy, the duration of hospitalization of patients infected with Botulinum
serotype A ranged from 37 to 78 days (Aureli et aL, 2000).
Botulinum toxin is released from bacteria as part of a noncovalent multimeric complex.
The auxiliary proteins that are best characterized are hemagglutinins (HA) and a nontoxin,
nonhemagglutinin (NTNH). This complex plays no critical role at the site of toxin action, but is
critical to the process of oral poisoning by providing resistance of the toxin to the low stomach
pH and proteolytic enzymes in the gastrointestinal system allowing delivery of the toxin to
vulnerable cells. (Simpson, 2004)
Active neurotoxin consists of a 100 kDa heavy chain and a 50 kDa light chain linked by a
disulfide bond. Crystalline structures of Botulinum neurotoxin indicate that the heavy chain
consists of a binding carboxyl domain and a translocation amino domain, while the light chain
contains a catalytic domain (Shukia and Sharma, 2005).

The likely mechanism allowing the

toxin to cross the membrane barriers in the lumen of the gut or airway is the binding to the apical
surface of epithelial cells leading to receptor-mediated endocytosis and/or transcytosis leading to
delivery to the basolateral surface of cells (Maksymowych and Simpson, 1998).
In order for the toxin to function, the following chain of events must occur: 1) the
carboxyl domain of the heavy chain binds to membrane receptors on the neuronal surface by
lock and key with little conformational change to the neurotoxin; 2) low affinity receptor binding
brings the neurotoxin in close proximity to bind to a second high affinity receptor allowing
endocytosis of the neurotoxin; 3) the heavy chain amino domain forms a channel mediating
translocation and the release of the light chain domain across the endosome membrane into the
terminal cytoplasm (Shukia and Sharma, 2005); 4) a conformational change induced by the
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acidic pH of the endosome allows the insertion of the neurotoxin into the endosomal membrane
mediated by dissociation of the amino terminus of the heavy chain from the light chains; and 5)
the catalytically active domain of the light chain is translocated from the lumen side to the
cytosolic side of the endosome. This occurs through the reduction of the disulfide bond that links
the light chain to the heavy chain, allowing for the movement of the light chain into a more
neutral environment (Simpson, 2004). Enzymatic cleavage of the protein components of the
neuroexocytosis apparatus by the light chain prevents the release of the neurotransmitter
acetyicholine from synaptic terminals of the motor neurons at the neuromuscular junction (US
Department of Health and Human Services, 1998) causing paresis in the target tissue.
Botulinum neurotoxin serotype A targets the SNAP-25 (soluble N-ethylmaleimide-sensitive
fusion attachment protein) of the SNARE (soluble NSF attachment protein receptors) complex.
The SNARE complex is a group of proteins essential for the docking and fusion to the synaptic
vesicles with the presynaptic membrane.
Six different forms of botulism exist. These include food-borne botulism (with
approximately half of the cases in the United States being caused by neurotoxin A (Shapiro et al.,
1998), wound botulism, infant botulism, adult form of infant botulism, inadvertent systemic
botulism and inhalation botulism (Arnon et al., 2001). The majority of human cases are infant
botulism. This form is more prevalent due to a lack of competing gut flora in infants. Food-borne
botulism is the second leading cause of botulism. Food-borne botulism, inadvertent systemic
and inhalational botulism all involve toxicity due to the exposure to preformed toxin (US
Department of Health and Human Services, 1998).
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Reference Arnon SS. JAMA February 28, 2001 Vol 285, No 8.

Figure 1. Release of acetylcholine at the neuromuscular junction is mediated by the
assembly of a synaptic fusion complex that allows the membrane of the synaptic vesicle
containing acetylcholine to fuse with the neuronal cell membrane. The synaptic fusion
complex is a set of SNARE proteins, which include synaptobrevin, SNAP-25, and syntaxin.
After membrane fusion, acetylcholine is released into the synaptic cleft and then bound by
receptors on the muscle cell. B, Botulinum toxin binds to the neuronal cell membrane at the
nerve terminus and enters the neuron by endocytosis. The light chain of botulinum toxin
cleaves specific sites on the SNARE proteins, preventing complete assembly of the synaptic
fusion complex and thereby blocking acetylcholine release. Botulinum toxins types B, D, F,
and G cleave synaptobrevin; types A, C, and E cleave SNAP-25; and type C cleaves
syntaxin. Without acetylcholine release, the muscle is unable to contract. SNARE indicates
soluble NSF-attachment protein receptor; NSF, N-ethylmaleimide-sensitive fusion protein;
and SNAP-25, synaptosomal-associated protein of 25 kd.
Food borne botulism is caused by vegetative cells of C. botulinum that release preformed
toxins in contaminated food.

The main factors for growth of C. botulinurn in food are: low

temperature, low pH, low water activity, redox potential, food preservatives and competing
microorganisms (US Department of Health and Human Services, 1998). Proteolytic strains of
the bacteria grow optimally at 4OC and a minimum pH of 4.6-4.8. The time to onset of the
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disease following a food borne exposure varies from several hours to 10 days, but most
commonly from 18-36 hours. Initial symptoms of food borne botulism are: nausea, vomiting,
abdominal cramps and diarrhea. Symptoms can progress into neurological problems such as
blurred vision and dry mouth with progression into descending paralysis (Shapiro et al., 1998).
Although some of the poisoned junctions may regain function, evidence of neuromuscular
deficits can persist for months (Sugiyama, 1980).

Electrophysiological evidence (supported by

histological evidence) suggests a correlation between recovery of muscle function and
development of new neuromuscular junctions (Sugiyama, 1980).
Deliberate release of Botulinum toxin in a civilian population food supply would cause
substantial disruption and distress. The Botulinum toxin is extremely potent, lethal and is easily
produced and transported. Infection with the toxin causes a need for prolonged intensive care
(Arnon et al., 2001). Between 90% and 100% of cases reported are admitted to the hospital, with
care lasting from one week to four or more weeks. (Przybylska, 1994) For this reason, the study
of C. botulinum in food sources is imperative to close gaps that might cause confusion or
question in the event of a bioterrorist attack. In addition, examination of the toxins stability in
different food matrices that could serve as a potential target for contamination requires further
investigation. It has been shown previously that fatty and proteinaceous foods increase potency
of orally administered botulinum toxin.

The exception being skim milk powder that showed

fewer deaths with toxin relative to the controls. (Lamanna and MEYERS, 1960) Currently, it is
thought that as many as 17 countries are suspected to include or to be developing biological
agents in their offensive weapons programs (Shapiro et al., 1998).
This study was performed to address recently identified critical gaps at a Bioshield
Scenario Planning Workshop pertaining to the determination of estimates of the number of
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people that could be affected through the introduction of Botulinum toxin serotype A into a bulk
milk source. A shipment of milk leaving a processing facility can contain between 4700 and
5400 gallons of pasteurized milk. Assuming that a family of 4 buys one gallon of milk the
possible number of people affected by the contamination would be 18, 800 * 21, 600 individuals.
Currently, the LD50 dose of Botulinum toxin serotype A has been determined when delivered
alone; however, no assessment of toxicity has been made for the toxin when delivered in milk.
The affects of the milk on the toxicity are in question. The objective of the proposed research is
to determine the oral LD50 for BoNT/A in adult guinea pigs when administered in 2% milk via
orogastric gavage. Perhaps the oral LD50 for BoNT/A will be lowered by the toxin being present
in milk, increasing the pH of the stomach allowing the toxin to pass more easily to the intestine.
The toxin would have a more stable environment for protection and be more available for uptake
in the intestines. The relative toxicity will be compared with that of the LD50 dose of BoNT/A
when delivered in gel phosphate buffer.
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PURPOSE
Hypothesis
The administration of Botulinum neurotoxin serotype A (BoNT/A) in fresh 2%
pasteurized milk will lower the LD50 in the adult guinea pig in comparison to the normal gel
phosphate buffer used in toxicity assays.
Specific Aims
The intent of this study was to address recently identified critical gaps pertaining to the
determination of estimates of the number of people that could be affected through the
introduction of Botulinum toxin serotype A into a bulk milk source.
1. To assess whether fresh 2% milk provides protective qualities for the toxin against
degradation in the gastrointestinal tract (e.g. stomach) lowering LD50 values in
comparison to toxin delivered in conventional gel phosphate buffer.
To view the pathophysiologic effects on guinea pigs after the oral administration of BoNT/A
through clinical observations and utilization of telemetry implants allowing examination of
changes in the mean, systolic, diastolic and pulse pressures, ECG, temperature, activity,
respiratory rate, QA interval, and heart rate.

7

METHODS
Test System
The model used for this study was adult male and female specific pathogen free Hartley
guinea pigs (caviae porcellus). 110 guinea pigs (7-11 weeks of age) all weighing approximately
500 grams, randomized into groups containing approximately equal numbers of males and
females were placed on study. Due to cost and availability, two guinea pigs (16-18 weeks of
age) received as gratis animals were also used on study. Only guinea pigs free of obvious clinical
signs of disease or malformations were utilized.

Animal dosing and tissue collection were

performed at Battelle Memorial Institute/Battelle Biomedical Research Center.
Prior to toxin dosing, each animal was conditioned with 1 ml of freshly pasteurized 2%
milk (Kroger Co., Tamarack Farms, Newark, Ohio) or control material gel phosphate buffer
(Battelle) dependent on their study group. Dose was set to be 3.25m1 (compared to the human
stomach holding a one cup serving of milk) However due to the guinea pigs not being able to
manage the volume - it was determined that animals would be dosed with 1 mL. During
conditioning and toxin dosing, the milk and gel phosphate buffer were administered via
orogastric gavage. For this study, "orogastric gavage" is defined as the insertion of a 2" stainless
steel 18 gauge needle with a ball tip inserted through the mouth and esophagus into the stomach.
Each animal was sedated prior to dosing with 0.2 ml of XylazineTM. Administered challenge
doses contained various levels of Botulinum neurotoxin serotype A.
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foNT/A in 2% milk LDo determination
The LD50 of the Botulinum neurotoxin serotype A in 2% milk was determined using a 3
phase approach via orogastric intubation challenges and compared to the control material,
Botulinum neurotoxin serotype A in gel phosphate buffer. Doses for later phases were selected
based on the cumulative results of earlier phases. The cumulative results from all three phases
were used to determine the LD50 dose of Botulinum neurotoxin serotype A in 2% milk and PB
and to determine any differences between the 2% milk and PB groups. Botulinum neurotoxin
serotype A characterized with a known mouse intraperitoneal lethal dose 50/mi (MIPLD50) was
used to prepare the required Botulinum neurotoxin serotype A in 2% milk and Botulinum
neurotoxin serotype A in gel phosphate buffer dosing solutions.
Determination of MIPLD50 Units (potency)
The determination of the MIPLD50 of the Botulinum neurotoxin serotype A was done by
a mouse potency assay prior to the start of the study. A MIPLD50 Unit is the quantity of toxin
which when injected intraperitoneally (IP) into mice, is expected to cause the death of 50% of
the mice within ninety-six hours. Botulinum toxins are quantitated by their potency or activity,
not weight and one unit of toxin is the LD50. The process to characterize the BoNT/A used in
this study included was done by these assay steps: 1) Obtaining mice weighing 18-22 grams, 2)
setting up multiple graded dilutions (in sterile gel phosphate buffer) of the Botulinum toxin, 3)
inject groups of mice IP with approximately 0.5 mL of toxin at each concentration, where the
number of mice per group was based on the required precision, 4) record the number of dead
mice as well as live mice per group daily for a period of four days (i.e. 96 E 2 hr from the time of
IP injection), and 5) assign the toxin stock vials the MIPLDso dose based on the number of
mouse deaths in MIPLDso units per mL using probit analysis.
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At a minimum, one experimental

group must have 50 percent or greater survival and one group, 50 percent or greater mortality for
the experimental results to be valid (i.e., the experimental curve must touch or span the 50
percent mortality level).
Preparation of BoNT/A-M and BoNT/A-PB
Prior to the day of oral dosing, the appropriate volume of Botulinum neurotoxin serotype A was
added and mixed with fresh 2% milk or gel phosphate buffer at 4°C to produce a 1.0 ml total
volume/animal dose.

The Botulinum neurotoxin serotype A in 2% milk and Botulinum

neurotoxin serotype A in gel phosphate buffer was kept at 4°C for 16-24 hours prior to use for
oral dosing. The dosing solution was kept overnight to establish the amount of time that the
product could be sitting on store shelves before the consumer purchases the contaminated
product. Due to volume problems (i.e. animals unable to tolerate larger volumes via oral gavage),
the originally desired dosing volume per animal [based on the percent volume (25%) occupied
by a one cup (237 ml) serving of milk of an adult human stomach (capacity of -940 ml)] of 3,25
ml could not be used and the volume was decreased to 1.0 ml.
The fresh 2% milk obtained from Tamarack Farms, Kroger Company in Newark OH
used in this study was within 12 hours of the pasteurization process when toxin was added. The
reason for using milk less than 12 hours post pasteurization was to make the situation as close to
an incidence of milk being contaminated prior to shipment to a grocery store. To verify the time
requirements, the processing and time of the pasteurization was obtained from the supplier of the
2% milk (Table 1).
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Table 1. Pasteurization Processing
Start
End
Time
Time
Date
10/11/2005
0645
0820
0820
10/19/2005
0630
11/1/2005
0445
0630
11/15/2005
0715
0850

Temp
(°F)
176
178
180.5
179

Cooled To
(°F)
36.5
36.5
36.5
36.5

Phase 1 Botulinum Serotype A Administration
Initially, fifty two guinea pigs were randomized into ten groups of 5 animals and one
group of 2 animals for dose day (Table 2). Due to limitations in the telemetry system, phase 1
was divided into two phases for oral dosing. However both phases were performed in the same
manner and will be combined in the phase 1 methods. On Study Day 0, each animal was lightly
sedated with 0.2 mL of XylazineTM (100 mg/mL) prior to oral dosing. Doses were delivered via
an 18-gauge 2-inch stainless steel feeding needle with a 2.4mm ball tip. Doses were given to all
groups except the control group as one of five MIPLD50 dose levels of Botulinum serotype A
diluted to desired levels in 1 mL of fresh 2% milk (groups 1-5) or gel phosphate buffer (groups
6-10) (Table 2). Group 1 consisted of 5 guinea pigs receiving a 2.9x 102 MIPLD50 oral dose of
Botulinum serotype A, group 2 consisted of 5 guinea pigs receiving a 9.4x102 MIPLD50 oral dose
of Botulinum serotype A, group 3 consisted of 5 guinea pigs receiving a 3.Ox iø MIPLD50 oral
dose of Botulinum serotype A, group 4 consisted of 5 guinea pigs that received a 9.6x 1 3
MIPLD50 oral dose of Botulinum serotype A, and group 5 consisted of 5 guinea pigs that
received a 3.1 xl 4 MIPLD50 oral dose of Botulinum serotype A, all delivered in 2% milk.
Groups 6-10 received the same dose level corresponding to Groups 1-5, respectively, with the
Botulinum serotype A only being delivered in gel phosphate buffer. Group 11 consisted of 2
animals and received 1 mL of 2% milk (no toxin) as the control group.
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Treatment Grouns

Treatment

Group

Guinea Pigs/Group

Phase

-Dose (MIPLD50s)

Milk
Milk
Milk
Milk
Milk
Phosphate Buffer
Phosphate Buffer
Phosphate Buffer
Phosphate Buffer
Phosphate Buffer
Milk Control

1
2
3
4
5
6
7
8
9
10
11

5
5
5
5
5
5
5
5
5
5
2

1
1
1
1
1
1
1
1
1
1
1

2.9x102
9.4x102
3.0x103
9.6x103
3.1x104
2.9 x 102
9.4 x 102
3.0 x i0
9.6 x i0
3.1 x i04
NA

Table 2. Phase 1

Phase 2 Botulinum Serotype A Administration
Thirty one guinea pigs were randomized into five groups of 5 animals, one group of 4
animals, and one group of 2 animals for day of dosing. Two females originally placed in group 2
were replaced prior to challenge with two females from group 4. Only one extra animal was able
to be replaced back into group 4. Oral dosing (performed as previously described) began on
Study Day 0 with each animal being sedated with 0.2 mL of XylazineT' (100 mg/mL).
As seen in Table 3 group 15 consisted of 4 guinea pigs due to the replacement of animals
in group 13. The replacement of animals from a gel phosphate buffer group to a milk group was
based on the number of animals being more important in the group of study interest. The milk
group is the basis for the whole study, whereas the gel phosphate group was used as a positive
control. Group 18 was dosed with 2% milk (no toxin) as a control group.

12

Treatment Groups

Table 3. Phase 2
Treatment

Group

Guinea Pigs/Group

Phase

-Dose (MIPLD50s)

Milk
Milk
Milk
Phosphate Buffer
Phosphate Buffer
Phosphate Buffer
Milk Control

12
13
14
15
16
17
18

5
5
5
4
5
5
2

2
2
2
2
2
2
2

5.OxlO'
l.6x 102
5.2x 102
5.0 x 10'
1.6 x 102
5.2 x 102
NA

Phase 3 Botulinum Serotype A Administration
Twenty six guinea pigs were randomized into four groups of 6 animals and one group of
2 control animals for day of dosing. One additional animal was added to each group in Phase 3
due to availability. Animals were anesthetized and dosed orally as previously described.

Table 4. Phase 3

-

Treatment Groups

Treatment

Group

Guinea Pigs/Group

Phase

-Dose (MIPLD50s)

Milk
Milk
Phosphate Buffer
Phosphate Buffer
Milk Control

19
20
21
22
23

6
6
6
6
2

3
3
3
3
3

1.9x102
3.3x102
2.3 x 102
3.6 x 102
NA
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Telemetry Monitoring
Telemetry readings were monitored and recorded once every 5 minutes for 30 seconds
during baseline and post-challenge observation periods via a transponder (C50-PXT, DSI, St
Paul, MN). C50-PXT transponders were surgically implanted in the peritoneal cavity of each
guinea pig at Charles River Laboratories. Each transponder consisted of two biopotential leads
(used to record ECG waveforms) and a pressure lead (used to record mean, systolic, diastolic and
pulse pressure values). Animal racks were set up with an individual receiver for each animal
cage, where each animal was caged individually. The receivers collected and transmitted data
through a data exchange matrix to a computer for data storage, viewing, and analysis. RPC-l
small animal and RMC-l large animal receivers (both compatible with the C50-PXT
transponder) were both used in the collection of data. Animals were staggered on the racks to
prevent any possible crosstalk between the receivers. The telemetry system was configured
before each phase of the study. The configuration identified the animals for each phase and their
respective position in the collection process. Baseline values were recorded beginning two days
prior to Study Day 0 for each phase. Depending on the time added to study, replacement animals
did not all have the full two day baseline.
Clinical Observations
Post-dosing, guinea pigs were observed three times daily until termination (day 6) for
clinical signs of illness and survivability due to Botulinum. All observations were done during
the normal working day, between the hours of 0600 and 1700. Deaths were recorded to the
nearest day and euthanasia to the nearest minute. Guinea pigs were observed for the following,
but not limited to, signs of illness: respiratory distress, not eating, dehydration, paralysis, eyelid
closure, rough hair coat, activity, moribund and death.
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Necropsy and Histopathology
Gross necropsies were performed throughout the 7 day observation period on all animals
found dead, euthanized due to illness, and on all animals surviving the 7 day post-dosing period
following euthanasia. All tissues taken were fixed in formalin and sent to EPL Archives
(Virginia) for archival; however, histopathology was not performed.
Sample Size
The sample size of 5 guinea pigs per dose-response curve was sufficient that the half
width of the 95 percent confidence interval for the LD50 was 30 percent or less. The half width
of the confidence interval depended on variability in the estimated LD50, which was a function of
the number of animals dosed, the slope of the dose-response curve, and the allocation of animals
to the dose-response relationship.
Statistical Methods
Probit dose-response models were fit using the SAS® (version 9.1) PROBIT procedure.
In order to determine if the two groups had the same dose-response relationship, separate models
were fit for each group. A likelihood ratio test was used to determine if the common slope model
adequately fit the data. Estimates for the LD50 and confidence intervals were calculated from the
probit dose-response model.
The LD50 ratio between the two treatment groups was computed in order to assess the
toxicity of Botulinum neurotoxin serotype A in 2% milk in comparison to gel phosphate buffer.
For the LD50 ratio, a 95 percent confidence interval was calculated using Fieller's theorem. Refer
to Finney (1971) for a more complete description of Fiellers theorem. A statistical hypothesis
test was conducted by comparing the LD50 ratio to one (unity) to determine whether the
estimated LD50s were significantly different from each other.
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For the analysis of time to death and time to clinical signs, a nonparametric survival
analysis procedure was used that incorporated right-censoring indicators for animals that
survived through time point 18 (one animal was observed for 19 time points). Since days to
death or clinical signs were a more informative measure than time points, the time points were
converted into days. There were three time points per day (morning, mid-day, and afternoon),
except for the first day where dosing was administered in the morning. To convert the time
points after dosing to days, the time points were simply divided by three. Thus, if an animal was
observed at the third time point (morning of day after dose) with some clinical sign then the days
to clinical sign would be 1. Descriptive statistics (mean and standard errors) of the days to death
and clinical signs were tabulated for each group using the Kaplan-Meier product limit method.
The LIFETEST procedure of SAS® (version 9.1) was used for this analysis. In order to adjust
for the different doses given in determining the effect of the group on days to death, Cox
proportional hazards modeling was used. The TPHREG procedure of SAS® (version 9.1) was
used for this analysis. The log base 10 of the dose was used for all analyses. The Cox model
included the treatment group, the dose effect and the interaction between treatment group and
dose.
Electrocardiographic Assessment
ECG waveform tracings were generated prior to the dosing and as scheduled throughout
the observation periods (i.e. 30 seconds every 5 minutes).

The ECG waveform strips were

qualitatively assessed for rhythm and morphology alterations by a board certified veterinary
cardiologist. ECG waveforms from the final 24 hours of life were viewed at approximately 1.5
second intervals each hour to show morphology and approximately 9 second intervals each hour
to show rhythm.
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MATERIALS
Test Material
The test material used in this study was Botulinum neurotoxin serotype A (Etiologic
ID# CBA1O2) (provided by Metabiologics, mc, Madison, WI) diluted to the desired toxin levels
in 2% milk or gel phosphate buffer prepared by Battelle (West Jefferson, OH). All dilutions
were based on the stock concentration of toxin of 2x 1 O MIPLD50/mL. The stock concentration
was previously determined by mouse potency assays where multiple graded dilutions of the
Botulinum toxin were dosed intraperitoneally into mice.
Control Material
The control materials used in this study were fresh 2% pasteurized milk provided by
Tamarack Farms of the Kroger Company or gel phosphate buffer formulated at Battelle. The 2%
milk was obtained from the supplier the same morning the toxin was to be added.
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RESULTS
Clinical Observations
A secondary goal of this study was to establish time to death and time to onset of clinical
signs, through clinical observations and the use of telemetry. Following dosing of the animals,
the clinical signs observed included dyspnea, dehydration, lethargy, rough hair coat, not eating,
paresis, and paralysis. Signs were most commonly observed in animals receiving lower dose
levels of toxin. Animals receiving higher doses of Botulinum neurotoxin serotype A in phase I
were commonly found dead within the first 24 hours post-dosing and no signs were observed.
However, when compared to data obtained from the telemetry monitoring, it is likely that clinical
signs would have been noted if more frequent observations were performed. The most common
clinical observations were dyspnea, lethargy, and rough hair coat. Control animals showed no
clinical signs of disease and were all normal at the conclusion of each phase of the study. In
addition, animals that were dosed in the later phases (i.e. lower toxin doses) also commonly
showed signs of paresis and paralysis along with increasing severity of dyspnea up to the time of
death. As compared to phase 1, phases 2 and 3 showed disease with animals in the higher dose
groups exhibiting prolonged clinical signs through the end of each phase. Each phase showed
that animals dosed with a higher LD50 fewer signs were exhibited. In phases 2 and 3, signs were
not seen until approximately forty-five to forty-eight hours post dosing. This shows that the LD50
was being narrowed and Botulinum has a delayed onset at lower doses. Compared to the last two
phases, phase 1 animals were found dead and exhibiting signs at less than twenty-four hours.
Probit dose-response models were fit using the SAS® (version 9.1) PROBIT procedure.
In order to determine if the two groups had the same dose-response relationship, separate models
were fit for each group. Then an additional model was fit in which the two groups were forced
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to have a common slope but individual intercepts, resulting in two parallel curves. A likelihood
ratio test was used to determine if the common slope model adequately fit the data. Estimates for
the LD50 and confidence intervals were calculated from the probit dose-response model.
The p-values indicate that there is no difference between the two treatment groups of 2%
milk and gel phosphate buffer with respect to the time to first clinical sign.

The Cox

proportional hazards model for the time to first non-normal clinical sign indicated that there was
no difference between the 2% milk group and the gel phosphate buffer group (p-valueO.6502)
but that dose did affect the time to onset (p-value<0.0001). This indicates that the dose-response
for time to onset of clinical signs was not significantly different between treatment groups. An
exception to the dose-response trend occurred in the milk group at the 160 MIPLD50 dose level,
where the lethality rate was greater than that observed at higher doses.

Table 5. Descriptive Statistics (Mean and Standard Errors) For Days to Death and Onset of
Clinical Signs and Log-Ranked P-Values for Testing Group Differences

Treatment Total # of
Animals
p
Milk

PB

-

Predicted
Mean (SE.)

52

3.72 (0.304)

51

3.82 (0.307)

Predicted Overall Group
Overall Group Mean (S.E.)
P-Value
(Clinical
P-Value
Days to
Clinical Sign
Sign)
0 8924
.
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{

2.69 (0.246)
_2.93 (0.282)

0 9376
____________

Mortality
A primary goal of this study was to assess the toxicity of Botulinum neurotoxin serotype
A when administered via orogastric gavage and delivered in 2% pasteurized milk or gel
phosphate buffer. Following dosing in phase 1, all animals in groups 3-5 (Botulinum serotype A
in 2% milk), and 7-10 (Botulinum serotype A in gel phosphate buffer) died with an average
group time to death of 1.0-2.0 days post-dosing. The average times to death, standard deviations,
and the ranges are summarized in Table 6. There was a decreased mortality rate and extended
average time to death in the two lower doses of toxin in milk (groups 1 and 2) and the lowest
dose of toxin in gel phosphate buffer (group 6) (see Table 6).

Generally, a dose-dependent

mortality rate and average time to death was observed in all groups except controls and group 1
listed in Table 6, whether the toxin was diluted in 2% milk or gel phosphate buffer. Animals in
group 11 that received 2% milk as the controls showed no mortality.
Based on the results of phase 1, where all animals succumbed to disease in all groups except for
the low dose group and one animal from the second to low dose, dose levels of Botulinum
neurotoxin serotype A in 2% milk or gel phosphate buffer were designed to bracket the lowest
dose during that phase. Levels for phase 2 were therefore set above and below 2.9x102
MIPLD50s. Within the phase, a dose-dependent mortality rate was seen in animals dosed with
either Botulinum neurotoxin serotype A in 2% milk or gel phosphate buffer (Table 7). There
were mortality rates of 0% (0/5), 60% (3/5), and 80% (4/5) for 2% milk groups 12 (low dose), 12
and 14 (high dose), respectively, in phase 2 (Figure 4). However in groups dosed with Botulinum
neurotoxin serotype A in gel phosphate buffer lethality was observed only shown in group 17
(high dose) with a 4/5 mortality (Figure 5). No mortality was shown in the milk only control
group 18.
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Table 6. Mortality Data Phase 1
Group
Dose
Number (MIPLD50s)
____

la

____

Number
Dead
_________

Avg time to

death
(days)

Std Dcv time
to death

Mm time to
death
(days)

Max time
to death
(days)

2.9x_102

2of5

3.0

1.4

2.0

4.0

94x 102

1 of 5

2.8

2.4

1.0

6.0

3a

3.Ox 10

5of5

1.2

0.4

1.0

2.0

4a

9.6x iø

5of5

1.0

0.0

1.0

1.0

_______

3.1x104

5of5

1.0

0.0

1.0

1.0

_______

2.9x 102

3ofS

4.7

1.2

4.0

6.0

_______

9.4x 102

5of5

2.0

0.7

1.0

3.0

3.Ox iø

5of5

1.0

0.0

1.0

1.0

9.6x 10

5of5

1.0

0.0

1.0

1.0

3.lx iø

5of5

1.2

0.4

1.0

2.0

Control
0 of 2
aBONT/A in milk
bBONT/A in gel phosphate buffer

NA

NA

NA

NA

_______

8"

_______

10"

21

Stage I Milk Treated

Figure 2. Mortality Data Graph - Botulinum Neurotoxin Serotype A in Milk Phase 1

Stage I Gel Phosphate Buffer Treated
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--------
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.

60%

_______

40%

-*--

20%
0%
0

1

2

4

3

5

6

7

Days

Figure 3. Mortality Data Graph - Botulinum Neurotoxin Serotype A in Gel Phosphate Buffer
Phase 1
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Due to the different mortality rates obtained in phase 2, doses chosen for phase 3 for
Botulinum neurotoxin serotype A in 2% milk differed from those in gel phosphate buffer (Table
9). Doses for the Botulinum neurotoxin serotype A in milk were chosen to target the estimated
LD40 (1.9 x 102 MIPLD50s) and LD60 (3.3 x 102 MIPLD50s) values (as well as bracket the
predicted LD50 value) as predicted by the previous two phases.

Doses for the Botulinum

neurotoxin serotype A in gel phosphate buffer were chosen to target the estimated LD25 (2.3 x
102 MIPLD50s) and LD65 (3.6 x 102 MIPLD50s) values. Mortality rates in phase 3 (Table 8) were
50% (3/6) and 0% (0/6) for groups 19 and 20 receiving the Botulinum neurotoxin serotype A in
milk and 67% (4/6), and 0% (0/6) for groups 21 and 22 receiving Botulinum neurotoxin
serotype A in gel phosphate buffer (Fig 6 and Fig 7). Animals in the 2% milk only control group
(phase 3, group 23) showed no mortality.
Overall, statistical evaluation using descriptive statistics for the days to death showed
through calculated p-values that there was no difference between the two treatment groups with
respect to the time to death. The Cox proportional hazards modeling also indicated that there
was no difference in time to death between the 2% milk and gel phosphate buffer groups (pvalue=0.4736), but that dose was highly significant (p-value<0.0001) in predicting the time to
death, which was consistent with the probit analysis. The interaction between treatment group
and dose was not significant and was dropped from the final model. This indicated that the doseresponse for time to death was not significantly different between treatment groups. The
summary of results for the LD50s for both treatment groups milk and gel phosphate buffer are
listed in Table 9.
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Table 7. Mortality Data Phase 2
Dose
Group
Number (MIPLDos)

Number
Dead

Jvgfimeto
death
(days)

StdDevtime
i

to death
(days)

Minfime
death
(days)

Maxtime
to death
(days)

12a

5.OxlO'

OofS

NA

NA

NA

NA

13k'

1.6x102

3of5

4.0

1.0

3.0

5.0

14a

5.2 x 102

4 of 5

3.0

1.4

2.0

5.0

15b

5.OxlO'

Oof4

NA

NA

NA

NA

l6'

1.6 x 102

0 of 5

NA

NA

NA

NA

5.2 x 102

4 of 5

3.0

0.8

2.0

4.0

Milk
Control

Oof2

NA

NA

NA

NA

18

Days

Figure 4. Mortality Data Graph

BoNT/A in Milk Phase 2
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Stage 2 Gel Phosphate Treated

Figure 5. Mortality Data Graph - BoNT/A in Gel Phosphate Buffer Phase 2
Table 8. Mortality Data Phase 3

Group
Number

Dose
(MIPLD50s)

Number
Dead

Avg time
to death
(days)

Std Dev time
to death
(days)

Mm time to
death (days)

Max time to
death (days)

19

1.9 x 102

0 of 6

NA

NA

NA

NA

20

3.3 x 102

3 of 6

2.3

0.6

2.0

3.0

21

2.3 x 102

0 of 6

NA

NA

NA

NA

22

3.6x 102

3.8

1.3

4of6
-

_

_-

2.0
_

5.0
__

___

23

Milk
Control

Oof2

NA

aBONT/A in milk
bB0NT/A in gel phosphate buffer
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NA

NA

NA

Stage 3 Milk Treated
60%
50%
40%

-.-Group 19
Group 20
Group 23

30%
20%
10%
0%
0

1

2

3

4

5

6

7

Days

Figure 6. Mortality Data Graph - BoNT/A in Milk Phase 3

Figure 7. Mortality Data Graph

BoNT/A in Gel Phosphate Buffer Phase 3
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Table 9. Summary Of Statistical Results From Probit Analysis
Probit Slope
Treatment

Total No.

Group

Animals Tested

________

Predicted LD5O

______

____

Slope

P-value

LDSO

95% Fieller's
Confidence
Bounds

Milk

52

2.42

0.0013

322.8

(193.4, 571.8)

PB

51

6.53

0.0030

349.0

(275.2, 479.6)

Telemetry Trends
Pre- and post-dosing data collected on this study by the telemetry system included mean,
systolic, diastolic, and pulse pressure, EKG, temperature, activity, respiratory rate, and heart rate.
Several common trends were seen in the guinea pigs following dosing with Botulinum
neurotoxin serotype A in 2% milk or gel phosphate buffer. These included the following: 1)
increases in heart rate followed by a decrease just prior to death, 2) pulse pressures also had a
tendency to rise just prior to the time of death, and 3) temperature showed a linear regression
with the heart rate in that as one decreased near the point of death the other dropped at a similar
rate. According to the telemetry data the best indicator of death appeared to be the pulse
pressure. Times of death were determined by the time at which the pulse pressure dropped below
zero. Animals that received lower doses of the Botulinum neurotoxin serotype A showed more
gradual decreases in data compared to the high dose groups.
Although the study was ended on study day 7, the telemetry data showed that had the
study been longer more animals could have succumbed to death. Animals that were observed
visually as being normal or showing minimal clinical signs, showed decreasing temperature,
blood pressures and slowing heart rates in the telemetry data.
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Figure 8. Dose Response Relationship for Both Milk and Gel Phosphate Buffer
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Telemetry Assessment
The results of the statistical analyses are presented in this section, separately by
parameter and treatment group. All references to statistical significance are at the 0.05 level,
unless specified otherwise in the methods section (e.g., comparisons of baseline averages among
pairs of treatment groups were done at the 0.05/3=0.0167 level; pairwise comparisons to control
group at a given post-dosing time point were done at the 0.05/10=0.005 level).
Body Temperature
For body temperature, significant dose effects started to present at 12 hours post-dosing
and continued through the ANOVA tested 24 hours period for both Botulinum neurotoxin
serotype A in 2% milk and Botulinum neurotoxin serotype A in gel phosphate buffer. The
highest dose levels (31000 and 9600 MIPLD50) showed significant differences from the control
group. Low and medium dose levels did not show significant differences from the control group.
The average body temperature also dropped significantly in the first two hours post-dosing, rose
back to baseline temperature level after about 5 hours, and then rose slightly above the baseline
level after

6 hours for the Botulinum neurotoxin serotype A in 2% milk and Botulinum

neurotoxin serotype A in gel phosphate buffer dose groups and the control group. For low and
medium dose levels, average body temperatures remained slightly above the baseline levels
throughout the 24 hour period for both Botulinum neurotoxin serotype A in 2% milk and
Botulinum neurotoxin serotype A in gel phosphate buffer dose groups.
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Figure 9. Graph is illustrating the average temperature for an animal being dosed in the Milk Dose Level 3.0x103
group. The temperature is shown dropping at the second event marker when the animal was anesthetized for dosing.
At event marker three the temperature is ascending to normal as the animal recovers from anesthesia. At 60 hours
plus the animal is succumbing to disease, representing by the drop in body temperature.
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Figure 10. Graph is illustrating the average temperature for an animal being dosed in the Milk Dose Level 9.4x 102
group. As seen in Figure 9, the temperature drops at time of anesthesia and recovers within ten hours of being dosed.
This animal represents an animal that was normal through the study but is seen to have a decline in temperature
towards the study end.
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Figure 11. Graph is illustrating the average temperature for an animal in the Milk Control group. This animal
shows the same drop in temperature at event marker one where anesthesia was given for dosing. At recovery, the
animal shows a return to normal temperature throughout the remainder of the study.

For the high dose levels, average body temperatures dropped significantly after 10-l2
hours and continued to drop until all animals died (dose level 31000 MIPLD50) or throughout the
plotted 24 hour period. It appeared that the average body temperature dropped more rapidly for
the high dose levels in Botulinum neurotoxin serotype A in gel phosphate buffer than in
Botulinum neurotoxin serotype A in 2% milk. It should be noted that the significant drop in
temperature near the time of dosing was likely due to the effects caused by the administration of
the anesthetic agents.
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Systolic Blood Pressure (SBP)
No significant dose effect on SBP in the first 24 hours post-dosing for Botulinum
neurotoxin serotype A in 2% milk. Botulinum neurotoxin serotype A in gel phosphate buffer,
shows a significant dose effect on SBP and was present at 18 and 23 hours post-dosing.
However, at 18 hours post-dosing, pairwise comparisons show that SBP in various Botulinum
neurotoxin serotype A in gel phosphate buffer dose levels were not significantly different from
SBP in the control group. At 23 hours post-dosing, SBP in the Botulinum neurotoxin serotype A
in gel phosphate buffer 9600 dose group (based on only one surviving animal) was significantly
different from SBP in the control group. The average SBP dropped significantly in the first two
hours post-dosing in all groups. The average SBP level rose in the next 2 hours (but did not
reach the original baseline level) and remained relatively steady after 4 hours post-dosing.
Generally, the control group had the lowest average SBP after 8 hours post-dosing. Before 8
hours post-dosing, many Botulinum neurotoxin serotype A in 2% milk and Botulinum
neurotoxin serotype A in gel phosphate buffer dose levels had lower average SBP than the
control group. In general, when comparing dose levels in groups, the high dose levels had higher
average SBP than medium dose levels and medium dose levels had higher average SBP than low
dose levels. It should be noted that the significant drop in SBP near the time of dosing was likely
due to the effects caused by the administration of the anesthetic agents.
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Figure 12. Graph is illustrating pressures for an animal dosed in the Milk Dose Level 5.2x102 group. In
descending order the graph lines represent systolic pressure on the top, then mean pressure, diastolic and the bottom
line represents the pulse pressure. This animal succumbed to disease within 48 hours of being dosed.
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Figure 13. Graph is illustrating pressures for an animal dosed in the Milk Dose Level 9.4xl02 group. In
descending order the graph lines represent systolic pressure on the top, then mean pressure, diastolic and the bottom
line represents the pulse pressure. This animal was found dead on the last day of study and is represented by a
gradual decline in body pressures.
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Figure 14. Graph is illustrating pressures for an animal dosed in the Milk Control group. In descending order the
graph lines represent systolic pressure on the top, then mean pressure, diastolic and the bottom line represents the
pulse pressure.

Diastolic Blood Pressure (DBP)
There was a significant dose effect on DBP at 24 hours post-dosing for Botulinum
neurotoxin serotype A in 2% milk and average DBP at the dose level of 31000 was significantly
different from the control (based on only 1 surviving animal).

The average DBP dropped

significantly in the first two hours post-dosing for Botulinum neurotoxin serotype A in 2% milk
group, rose back within an hour to the level of first hour immediately post-dosing, but remained
below the original baseline level.

The average DBP level remained relatively steady after 4

hours post-dosing for Botulinum neurotoxin serotype A in 2% milk group.

Generally, the

control group had the lowest average DBP after 8 hours post-dosing. Between 5 and 17 hours
post-dosing. the highest average DBP was found in Botulinum neurotoxin serotype A in 2% milk
3000 dose level.
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Botulinum neurotoxin serotype A in gel phosphate buffer, shows a significant dose effect
on DBP at 1 and 17 to 23 hours post-dosing. However, at the 1, 19, 20, 21, and 24 hours postdosing, pairwise comparisons show that DBP in various Botulinum neurotoxin serotype A in gel
phosphate buffer dose levels were not significantly different from DBP in the control group. At
17 hours post-dosing, DBP in Botulinum neurotoxin serotype A in gel phosphate buffer 31000
dose level (based on 3 animals) was significantly different from DBP in the control group; at the
18 hours post-dosing, DBP in the Botulinum neurotoxin serotype A in gel phosphate buffer
31000 dose level (based on only 1 animal) was significantly different from DBP in the control
group; and at 22 and 23 hours post-dosing, DBP in the Botulinum neurotoxin serotype A in gel
phosphate buffer 9600 dose level (based on only 1 animal) was significantly different from DBP
in the control group.

For the 50, 3000, and 9600 Botulinum neurotoxin serotype A in gel

phosphate buffer dose levels, the average DBP rose above baseline in the first hour immediately
post-dosing, dropped significantly in the 2x hour post-dosing, and then rose back to a DBP level
in line with other dose levels. The average DBP for the other Botulinum neurotoxin serotype A
in gel phosphate buffer dose groups dropped continuously over the first two hours immediately
post-dosing, rose and dropped back to the level of hour 2 post-dosing, and remained relatively
steady after 6 hours post-dosing (but still below the original baseline level).

Except for the

Botulinum neurotoxin serotype A in gel phosphate buffer 230 dose group, the control group had
lowest average SBP after 8 hours post-dosing. Among all Botulinum neurotoxin serotype A in
gel phosphate buffer dose groups, the Botulinum neurotoxin serotype A in gel phosphate buffer
230 dose group had the lowest average DBP between 2 and 16 hours post-dosing.
It should be noted that the significant drop in DBP near the time of dosing was likely due
to the effects caused by the administration of the anesthetic agents.
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Mean Arterial Pressure (MBP)
There was no significant dose effect on MBP in the first 24 hours post-dosing for
Botulinum neurotoxin serotype A in 2% milk. The average MBP dropped significantly in the
first two hours post-dosing for the Botulinum neurotoxin serotype A in 2% milk group, rose back
within an hour to the level of first hour immediately post-dosing, and then dropped slightly to a
relatively steady level after 4 hours post-dosing. The average MBP level remained relatively
steady after 4 hours post-dosing for Botulinum neurotoxin serotype A in 2% milk group.
Generally, the control group had lowest average MBP after 8 hours post-dosing.
For Botulinum neurotoxin serotype A in gel phosphate buffer, a significant dose effect on
MBP was present at 1, 18, and 23 hours post-dosing. However, at the first hour post-dosing,
pairwise comparisons show that MBP in various Botulinum neurotoxin serotype A in gel
phosphate buffer dose levels were not significantly different from the MBP in the control group.
At 18 hours post-dosing, the MBP in the Botulinum neurotoxin serotype A in gel phosphate
buffer 31000 dose level (based on only one animal) was significantly different from MBP in the
control group. At 23 hours post-dosing, the MBP in the Botulinum neurotoxin serotype A in gel
phosphate buffer 9600 dose level (based on only one animal) was significantly different from
MBP in the control group. The average MBP in the Botulinum neurotoxin serotype A in gel
phosphate buffer 9600 dose levels rose slightly above baseline level in the first hour immediately
post-dosing, dropped significantly in the 2' hour post-dosing, and then rose back to the MBP
level in line with other dose levels.

The average MBP for the other Botulinum neurotoxin

serotype A in gel phosphate buffer dose groups dropped significantly and continuously in hours
1 and 2 immediately post-dosing, and then rose and then dropped back to the level of first hour
immediately post-dosing and remained relatively steady after 4 hours post-dosing but still below
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the original baseline level. Except for the Botulinum neurotoxin serotype A in gel phosphate
buffer 230 dose group, the control group had lowest average MBP after 8 hours post-dosing.
Among all Botulinum neurotoxin serotype A in gel phosphate buffer dose groups, the Botulinum
neurotoxin serotype A in gel phosphate buffer 230 dose group had the lowest average DBP
between 4 and 16 hours post-dosing. It should be noted that the significant drop in MBP near the
time of dosing was likely due to the effects caused by the administration of the anesthetic agents.
Pulse Pressure (PBP)
There was a significant dose effect on PBP at 20, 21, and 22 hours post-dosing for the for
Botulinum neurotoxin serotype A in 2% milk groups.

The average PBP at the 9600 and 31000

dose levels in the for Botulinum neurotoxin serotype A in 2% milk groups were significantly
different from the control group at 20 and 21 hours post-dosing.

The average PBP at the for

Botulinum neurotoxin serotype A in 2% milk 9600 dose level was significantly different from
the control at 22 hours post-dosing. The average PBP dropped significantly in the first two hours
post-dosing for the for Botulinum neurotoxin serotype A in 2% milk group before gradually
rising back to the baseline level after 8 hours post-dosing.

One exception is the for Botulinum

neurotoxin serotype A in 2% milk 180 dose group whose PBP rose over the baseline level at 6
hours post-dosing and stayed above baseline level until 16 hours post-dosing. From 10 to 24
hours post-dosing, the average PBP was consistently higher than baseline for for Botulinum
neurotoxin serotype A in 2% milk dose groups 330, 3000, and 9600. Generally, the control
group had a lower average PBP after 8 hours post-dosing in comparison to the for Botulinum
neurotoxin serotype A in 2% milk group.
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For the Botulinum neurotoxin serotype A in gel phosphate buffer, a significant dose
effect on PBP was shown from 14 to 22 hours post-dosing. Pairwise comparisons show that the
PBP in the 9600 and/or 31000 Botulinum neurotoxin serotype A in gel phosphate buffer dose
levels were significantly different from PBP in the control group. The average PBP dropped
significantly in the first two hours post-dosing for the Botulinum neurotoxin serotype A in gel
phosphate buffer group, and for most dose groups, gradually rose back to the baseline level and
remained steady after 8 hours post-dosing. The exceptions were in the Botulinum neurotoxin
serotype A in gel phosphate buffer 50 dose group whose average PBP level remained well below
baseline level after received the toxin and the three highest Botulinum neurotoxin serotype A in
gel phosphate buffer dose groups, 3000, 9600, and 31000 whose average PBP level rose past the
baseline level after 11 hours post-dosing and continued rising for at least 5 hours. It should be
noted that the significant drop in PBP near the time of dosing was likely due to the effects caused
by the administration of the anesthetic agents.
Heart Rate
There was a significant dose effect on heart rate at 2, 12, 13, and 15 to 24 hours postdosing for the Botulinum neurotoxin serotype A in 2% milk groups. However, at the 2 and 15
hours post-dosing, pairwise comparisons show these heart rates in the various Botulinum
neurotoxin serotype A in 2% milk dose levels were not significantly different from the heart rate
in the control group. The average heart rate at the 31000 dose level in Botulinum neurotoxin
serotype A in 2% milk was significantly different from the control group at 12 and 13 hours
post-dosing. The average heart rate at the 9600 dose level in Botulinum neurotoxin serotype A
in 2% milk was significantly different from the control group at 16 to 24 hours post-dosing. The

average heart rate at the 3000 dose level in Botulinum neurotoxin serotype A in 2% milk was
significantly different from the control at 21 to 24 hours post-dosing.

The average heart rate

dropped significantly in the first hour immediately post-dosing for the Botulinum neurotoxin
serotype A in 2% milk group, rose back to baseline level between 2-3 hours post-dosing, and
continued to rise above the baseline level after 3 hours post-dosing. In the low dose groups (50,
160. 180), the heart rate gradually decreased back to baseline levels after 20 hours post-dosing.
In the high dose groups (3000, 9600, 31000), the heart rates were lower than the control group
between 4-6 hours post-dosing. At about 7 hours post-dosing, the heart rate in animals in the
highest dose group (31000) raised past the levels in the control group and gradually dropped
until animal died. At about 11 hours post-dosing, heart rates in animals in the second highest
dose group (9600) raised past the levels in the control group and gradually dropped until animal
died. At about 12 hours post-dosing, heart rates in animals in the third highest dose group (3000)
raised past levels in the control group and remained strong for at least 8 hours until gradually
dropping prior to death.
There was a significant dose effect on the heart rate at 13 to 24 hours post-dosing for the
Botulinum neurotoxin serotype A in gel phosphate buffer. However, at 13 hours post-dosing,
pairwise comparisons show that the heart rates in the various Botulinum neurotoxin serotype A
in gel phosphate buffer dose levels were not significantly different from the heart rate in the
control group. The average heart rate at the 31000 dose level in Botulinum neurotoxin serotype
A in gel phosphate buffer was significantly different from the control group at 14 to! 8 hours
post-dosing. The average heart rate at the dose level of 9600 in Botulinum neurotoxin serotype
A in gel phosphate buffer was significantly different from the control group at 15 to 24 hours
post-dosing. The average heart rate at the dose level of 3000 in Botulinum neurotoxin serotype
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A in gel phosphate buffer was significantly different from the control group at 19 to 24 hours
post-dosing. The average heart rate dropped significantly in the first hour immediately postdosing for the Botulinum neurotoxin serotype A in gel phosphate buffer group, rose back to
baseline level between 2-3 hours post-dosing, and then continued to rise above baseline level
after 4 hours post-dosing. For the low dose groups (50, 160, 180), similar to the Botulinum
neurotoxin serotype A in 2% milk groups, the heart rate gradually decreased back close to
baseline level after 20 hours post-dosing. For two highest dose groups (9600 and 31000), the
heart rates were lower than the control group from 3 hours post-dosing until death.

It

should be noted that the significant drop in heart rate near the time of dosing was likely due to
the effects caused by the administration of the anesthetic agents.
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Figure 15. Graph is illustrating the heart rate for an animal dosed in theMilk Dose Level 94x102 group.
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Figure 16. Graph is illustrating the heart rate for an animal in the Milk Control group.

Respiratory Rate
There was a significant dose effect on respiratory rate at 2, 3, 11, 12, 14 to 21, and 24
hours post-dosing for Botulinum neurotoxin serotype A in 2% milk. However, at the 2, 3, 14,
15, 19, 20, 21, and 24 hours post-dosing, pairwise comparisons showed that the respiratory rates
in various Botulinum neurotoxin serotype A in 2% milk dose levels were not significantly
different from the respiratory rate in the control group. The average respiratory rate at the 31000
dose level in Botulinum neurotoxin serotype A in 2% milk was significantly different from the
control at 11 and 12 hours post-dosing. The average respiratory rate at the 9600 dose level in
Botulinum neurotoxin serotype A in 2% milk was significantly different from the control group
at 16 to 18 hours post-dosing. For the control group, the average respiratory rate dropped
significantly in the first hour immediately post-dosing, rose back close to the baseline level at
about 3 hours post-dosing, and then remained stable throughout the 24 hours. For the lowest
dose group (50), the average respiratory rate was both up and down after 2 hours post-dosing.
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For the other two low dose groups (160 and 180), the average respiratory rate dropped slightly
within the first hour post-dosing rose above the baseline level between 2-3 hours post-dosing,
and generally remained stable after that.

For one medium dose group (520), the average

respiratory rate dropped slightly within the first hour post-dosing, rose above the baseline level at
about 3 hours post-dosing, and generally remained stable after that. For the other three medium
dose groups (290, 330, and 940), the average respiratory rate showed little change immediately
after dosing, rose above baseline after 2-3 hours post-dosing and generally remained stable after
that. At about 7 hours post-dosing, animals in the highest dose group (31000), their average
respiratory rate started to drop until animal died. At about 8 hours post-dosing, the average
respiratory rate in animals in the second highest dose group (9600) dropped until the animal died.
There was a significant dose effect on respiratory rate at 3 to 6 and 9 to 23 hours postdosing for Botulinum neurotoxin serotype A in gel phosphate buffer. However, at 3 to 6, 9, 11,
16, 19, 20, 21, and 23 hours post-dosing, pairwise comparisons did not show significant
differences of the various Botulinum neurotoxin serotype A in gel phosphate buffer dose levels
from the respiratory rate in the control group.

The average respiratory rate at the 31000

Botulinum neurotoxin serotype A in gel phosphate buffer dose level was significantly different
from the control at 10, 12, 13 and 14 hours post-dosing. The average respiratory rate at the 9600
Botulinum neurotoxin serotype A in gel phosphate buffer dose level was significantly different
from the control group at 15 to 18 hours post-dosing. The average respiratory rate at the 3000
Botulinum neurotoxin serotype A in gel phosphate buffer dose level was significantly different
from the control at 17 to 22 hours post-dosing. For the control group, the average respiratory
rate dropped significantly in the first hour immediately post-dosing, rose back near the baseline
level at about 3 hours post-dosing, and then remained relatively stable throughout 24 hours. For
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the two lowest dose groups (50 and 160), the average respiratory rate was up and down from 4
hours post-dosing until the 24 hour time point. In the other low dose group (230), the average
respiratory rate dropped slightly during the first hour post-dosing, rose immediately above
baseline level, and then remained higher than baseline. For one medium dose group (520), the
average respiratory rate dropped slightly within the first hour post-dosing and remained below
baseline throughout 24 hours. For the other two medium dose groups (290 and 360), the average
respiratory rate dropped slightly after dosing but rose above baseline after 2-3 hours post-dosing
and then remained stable.

Beginning at about 7, 9, or 10 hours post-dosing, the average

respiratory rate dropped until death in animals in the dose group 31000, 9600, and 3000,
respectively. It should be noted that the significant drop in respiratory rate near the time of
dosing was likely due to the effects caused by the administration of the anesthetic agents.
QA Interval
There was a significant dose effect on QA interval at 2 to 10, 18, 20, and 23 hours postdosing for Botulinum neurotoxin serotype A in 2% milk. However, except at 2 hours postdosing, pairwise comparisons showed that the QA intervals in various Botulinum neurotoxin
serotype A in 2% milk dose levels were not significantly different from QA intervals in the
control group. At 2 hours post-dosing, the average QA interval at the 940 Botulinum neurotoxin
serotype A in 2% milk dose level was significantly different from the control group. The
average QA interval in the Botulinum neurotoxin serotype A in 2% milk dose groups increased
significantly in the first hour immediately post-dosing, dropped significantly for the next 2 hours,
continued to decrease below baseline until 7 hours post-dosing, and remained steady thereafter.

There was a significant dose effect on QA interval at 1, 3, 4, 8 to 10, and 13 to 21 hours
post-dosing for Botulinum neurotoxin serotype A in gel phosphate buffer. However, except for
1, 8. and 9 hours post-dosing, pairwise comparisons showed that the QA intervals in the various
Botulinum neurotoxin serotype A in gel phosphate buffer dose levels were not significantly
different from QA intervals in the control group. At 1 hour post-dosing, the average QA interval
at the 9600 Botulinum neurotoxin serotype A in gel phosphate buffer dose level was significantly
different from the control. At 8 and 9 hours post-dosing, the average QA interval at the 230
Botulinum neurotoxin serotype A in gel phosphate buffer dose level was significantly different
from the control.

The average QA interval in the Botulinum neurotoxin serotype A in gel

phosphate buffer dose groups increased significantly in the first hour immediately post-dosing,
dropped significantly for the next 2 hours, continued to decrease below baseline at about 7 hours
post-dosing, and for most Botulinum neurotoxin serotype A in gel phosphate buffer dose groups,
remained steady below baseline afterwards. The average QA interval levels in the Botulinum
neurotoxin serotype A in gel phosphate buffer 50 dose group rose above baseline level at about
17 hours post-dosing and stayed above baseline throughout 24 hours. The average QA interval
levels in the Botulinum neurotoxin serotype A in gel phosphate buffer 520 dose group rose
slightly above baseline level at about 8 hours post-dosing, dropped back to baseline in the next
three hours, rose and stayed above baseline for the remainder of the 24 hours. It should be noted
that the significant increase in QA interval near the time of dosing was likely due to the effects
caused by the administration of the anesthetic agents.
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Activity
One significant dose effect for Botulinum neurotoxin serotype A in 2% milk on activity
level was found (8 hours post-dosing). However, pairwise comparisons showed the activity level
at 8 hours post-dosing in various Botulinum neurotoxin serotype A in 2% milk dose levels were
not significantly different from the activity level in the control group. The average activity level
in the Botulinum neurotoxin serotype A in 2% milk dose groups decreased slightly in the first 7
hours post-dosing and rose above baseline at 8 hours for all dose levels prior to dropping back
close to baseline levels the next hour.
Only one significant dose effect for Botulinum neurotoxin serotype A in gel phosphate
buffer on activity level was found (8 hours post-dosing). Pairwise comparisons showed that at 8
hours post-dosing, the average activity level at the 3000 Botulinum neurotoxin serotype A in gel
phosphate buffer dose level was significantly different from the control group.

The average

activity level jumped 8 hours post-dosing only in the Botulinum neurotoxin serotype A in gel
phosphate buffer 160 and 230 dose groups.

Other dose groups did not show a jump in activity

level and remained below the baseline levels throughout the 24 hours post-dosing. The lowest
activity level was found in the Botulinum neurotoxin serotype A in gel phosphate buffer 3000
dose group.
ECG
ECG findings showed clear and obvious changes in rates and rhythms attributable to the
Botulinum neurotoxin serotype A; however, there appeared to be no differences in ECG's
between formulations of Botulinum neurotoxin serotype A in gel phosphate buffer or in 2%
milk. ECG's showed a slight increase in heart rate approximately 24 hours prior to death. At
approximately 6 to 8 hours before death changes in ECG's showed: 1) a decrease in heart rate
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which became slower with time, 2) as the heart rate slowed, the sinus arrhythmia became more
exaggerated, 3) J point depression and or change in configuration of ST-T generally became
greater with time, 4) supraventricular and ventricular premature depolarizations, and short
periods of paroxysmal ventricular tachycardia with one incidence of ventricular bigeminy, and 5)
rare incidences of 2'' degree AV block. Approximately 1 hour before death heart rate slowed
precipitously, and ST-T became more bizarre where the J point was dramatically depressed.
At death, guinea pig number 57 developed either torsades de pointes or ventricular
fibrillation, but then developed sinus arrest or 3

degree AV block with a slow idio-ventricular

rhythm. All guinea pigs developed the sinus arrest except for animal number 144. Guinea pig
number 144 had no substantive changes in BCG's, and at the time of death the ECG appeared to
be within normal limits.
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Figure 17. Baseline Reading for an animal in the dose level 5.2x102 group.
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Figure 18. 6 Hours Prior to Death for dose level 5.2x 102, shows a decrease in heart rate with sinus arrhythmia.
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Necropsy and Histopathology
Complete gross necropsies were performed on all animals (except #20 and #119) during
the seven day observation period when found dead or euthanized. All surviving animals at the
end of the seven day period were also necropsied. As expected no animals died due to disease
and only incidental gross findings were observed. In phase 1 animal #121 had dark red diffuse
discoloration of the lungs, #100 had dark red diffuse discoloration of the lungs and a cyst on the
left uterine horn, #8 was found to show dilatation in the right kidney of approximately five times
the normal size, and #101 and #9 had approximately 20 milliliters of fluid in the abdominal
cavity. In phase 2, animal #131 and #44 had approximately 20 - 30 milliliters of fluid in the
abdominal cavity. No gross findings were observed in animals from phase 3.
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DISCUSSION
In this study, we assessed the protective qualities pro'ided to Botulinum neurotoxin
serotype A by fresh 2% milk against degradation in the gastrointestinal tract (e.g. stomach) of
male and female Hartley guinea pigs. This assessment was used to see if the milk would aid in
lowering the oral LD50 values in comparison to Botulinum neurotoxin serotype A in gel
phosphate buffer (the traditional dosing solution). We also viewed the clinical observations and
the pathophysiologic effects through the utilization of telemetry. Each animal that transmitted a
signal was monitored for post-dosing alterations in mean, systolic, diastolic, and pulse pressures,
ECG, temperature, activity, respiratory rate, QA interval, and heart rate.
Clinical observations taken for 7 days post-dosing showed few to no signs for animals in
the three highest dose groups 3.0 x 1 3, 9.6 x 1 3, and 3.1 x 1 o4 for animals dosed with
Botulinum neurotoxin serotype A in milk or gel phosphate buffer. The animals from the gel
phosphate buffer groups died less than 24 hours following dosing and were found dead the
following morning. Animals in the two higher milk groups were found dead within 24 hours,
however the dose group 3.0 x 1 3 had animals showing signs at 24 hours and were found dead
within 48 hours. Animals that died between 24 and 48 hours most commonly showed signs of
dyspnea, lethargy, paresis, and dehydration (a result of rapid onset of the disease and inability for
the animals to reach water due to paralysis). Groups from all three phases that received the
higher doses and had deaths occurring beyond 48 hours of dosing showed signs over several
observation periods and/or days with the most common being dypsnea. lethargy. and rough hair
coat. There were a few animals, mostly in the low dose groups. that showed signs and did not
succumb to the toxins effects. These animals were in groups 1 and 6 from phase 1, group 16
from phase 2 and groups 20. 21, and 22 from phase 3.
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A primary objective of this study wns to assess the mortality rate, time to death, and LD50
values for Botulinum toxin dosed in fresh 2% milk or gel phosphate buffer. Mortality rates were
shown to be dose-dependent among all phases except group 13 in phase 2 where the lethality rate
was higher than observed in the previous three higher doses. The average time to death could be
predicted by the dose level, but was not significantly different between the two treatment groups.
The milk appeared to have no protective factor against Botulinum neurotoxin serotype A.
The LD50 ratio between the two treatment groups was computed in order to assess the
toxicity of Botulinum neurotoxin serotype A in 2% milk in comparison to gel phosphate buffer.
The LD50 for Botulinum neurotoxin serotype A in 2% milk was 322.8 with a confidence interval
of (193.4, 571.8) and for Botulinum neurotoxin serotype A in gel phosphate buffer the LD50 was
349.0 with a confidence interval of (275.2, 479.6). Although the confidence intervals overlap,
the point estimates at the LD90 and LD95 are 2 to 3 fold greater for the 2% milk buffer and the
confidence intervals are wider.

The test for the LD50 ratio indicated that the ratio did not

significantly differ from one another (p-value0.7502) which indicated that the LD50s do not
differ. Although the LD5O was lower in the milk groups there was no indication that the milk
was protective for the Botulinum neurotoxin serotype A and was not statistically significant. The
protection for the toxin could have been from the amount of fat in the milk that increased the
transit time through the stomach and rate of absorption.
Pre- and post-dosing data collected on this study by the telemetry system included mean,
systolic, diastolic, and pulse pressure, ECG, QA interval. temperature, activity, respiratory rate,
and heart rate.
Body temperature has shown to be a highly predictable indicator of death. For the high
dose levels the average body temperatures dropped significantly after 10 to 12 hours and
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continued to drop until death. In the high dose levels, when the body temperature began to drop.
it appeared to be more rapid in the Botulinum neurotoxin serotype A in gel phosphate buffer than
in Botulinum neurotoxin serotype A in 2% milk. For the mean of the animals in the high dose
group of Botulinum neurotoxin serotype A in gel phosphate buffer, when the temperature
dropped it never came back up as compared to the Botulinum neurotoxin serotype A in milk
where the temperatures fluctuated up and down.
Blood pressure measurement effects were also dependent on the dose levels of toxin, but
not the formulation in which the toxin was delivered. In general, when comparing dose levels,
the high dose levels had higher average pressures than medium dose levels and low dose levels.
All pressures dropped immediately post dosing most likely due to the affects of the anesthetic
used prior to oral gavage. By 8 hours post-dosing, many Botulinum neurotoxin serotype A in
milk and Botulinum neurotoxin serotype A in gel phosphate buffer dose levels had lower average
SBP than the control group.
Heart rates and respiratory rates were also found to be good indicators of death. The three
highest dose levels showed a dose dependent effect for Botulinum neurotoxin serotype A in both
gel phosphate buffer and milk. As the animals recovered from anesthesia post dosing, their heart
rates and respiratory rates increased above baseline levels. When death was imminent they
gradually decreased and continued dropping until death. Both the increase and decrease to death
are indicative of disease caused by the toxin.
The telemetry data showed that if the observations would have gone longer, more animals
could have succumbed to death; although animals were observed as normal their telemetry data
showed decreasing temperature. blood pressures and slowing heart rates.

51

The results of the ECG's showed that the toxin had an affect on the functions of the heart,
but the extreme bradycardia most likely reflected terminal hypoxia resulting from respiratory
arrest. The respiratory arrest would have resulted from the dosing of the Botulinum neurotoxin
serotype A in gel phosphate buffer or in milk.
Increases in the heart rate likely resulted from one or a combination of factors including
pain, fever, excitement, a drug effect on baroreceptor function; decrease in systemic arterial
pressure, or by a direct effect on ion channels specific for SA nodal automaticity. The reduction
in heart rate could have been caused by the opposite effects or to hypothermia. This would be
relative to the progression of disease post-dosing. The augmentations of sinus arrhythmia and
apparent gasping (indicated on the ECG's by the voltage fluctuations and muscle tremor artifact)
were likely interrelated.
The retained stability of the toxin in milk indicates that the introduction of the toxin into
a supply of milk could cause significant morbidity, mortality, and impact on the economy due to
the resulting panic. The importance of this study doesn't only come from the results of the
clinical signs, but from the amount of telemetry data collected on the guinea pig model. Between
the clinical observations and the use of telemetry implants, Botulinum toxin serotype A was
shown to be the cause of death. The telemetry data also gives baseline data for guinea pigs prior
to dosing that can be referenced in other guinea pig studies.
From this study we cannot have a full understanding of the properties of milk that will
directly affect the toxicity level of the Botulinum toxin serotype A. Based on the findings of
mortality rates, time to death and onset of disease this study indicates that there is no significant
change in the toxicity of Botulinum toxin serotype A whether delivered in fresh pasteurized 2%
milk or in gel phosphate buffer. Mortality rates are dose dependent no matter which treatment
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the guinea pigs received and time to death can be predicted by dose level. These results conclude
that no change was evident to the Botulinum toxin serotype A over a 24 hour period.
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